14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CNVS vs AIMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Cineverse Corp. (CNVS) is the stronger overall head-to-head candidate over Ainos, Inc. (AIMD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CNVS carries a Unified Composite Score of 35.9/100 (SELL) at $1.73 (38.8x Forward P/E, -12.0% operating margin), whereas AIMD carries 23.4/100 (STRONG SELL) at $1.18 (13.9x Forward P/E, -101210.2% operating margin).
Defensive Composite Rating Caution: Although CNVS compares more favorably head-to-head, both CNVS (35.9/100 SELL) and AIMD (23.4/100 STRONG SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Competes within the Scientific & Technical Instruments value chain with $8.4M market capitalization and -101210.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CNVS vs AIMD Key Questions & Quantitative Answers
As of Nov 20, 2026, Cineverse Corp. (CNVS) is the stronger overall head-to-head candidate over Ainos, Inc. (AIMD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CNVS carries a Unified Composite Score of 35.9/100 (SELL) at $1.73 (38.8x Forward P/E, -12.0% operating margin), whereas AIMD carries 23.4/100 (STRONG SELL) at $1.18 (13.9x Forward P/E, -101210.2% operating margin). Defensive Composite Rating Caution: Although CNVS compares more favorably head-to-head, both CNVS (35.9/100 SELL) and AIMD (23.4/100 STRONG SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
CNVS leads the Growth & Scale pillar: CNVS posts +110.0% YoY revenue growth and +21.1% YoY earnings growth on $99M TTM revenue (42.7% gross margin, -12.0% operating margin), compared with AIMD at -96.7% YoY revenue growth and +0.0% YoY earnings growth on $13,600 TTM revenue (78.7% gross margin, -101210.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), CNVS cumulative revenue shifted +40.0% while AIMD shifted N/A. In operating R&D and SG&A reinvestment, CNVS deploys 54.7% of Rev ($54M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AIMD.
AIMD screens cheaper on headline valuation multiples. CNVS trades at 38.8x Forward P/E, 38.8x Trailing P/E, 0.46x PEG, and 0.7x EV/Revenue (-17.9% FCF margin), whereas AIMD trades at 13.9x Forward P/E, 13.9x Trailing P/E, 0.93x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNVS (-4.6% ROE) versus AIMD (-196.3% ROE) capital efficiency.
In options market volatility and institutional positioning, CNVS carries 131.8% implied volatility (28th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 110% Vol realized risk). By comparison, AIMD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.03β · 437% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.